Triple Threat: Full Rhinosinusitis Data Place Dupixent Top Of The IL Heap

 
• By Jo Shorthouse

Sanofi and Regeneron take a big step forward to building an allergy franchise off the back of newly released data from latest Dupixent trials in severe chronic rhinosinusitis with nasal polyps.

Crowns
Dupixent is about to add another indication to its roster • Source: Shutterstock

More from Clinical Trials

More from R&D